Monika advises on the reimbursement of the costs of treatment obtained outside Poland
Monika advised the parents of a newborn with rare heart disorders in proceedings concerning reimbursement from the National Health Fund of the costs of very complicated surgery treatment obtained abroad (several hundred thousand zlotys). The President of the NFZ (National Health Fund) approved the reimbursement of these costs in full.
Monika as one of the authors of IZWOZ reports
Monika Duszyńska is one of the authors of the extensive report published by the Institute of Health Management at Lazarski University. "Reasons of a limited availability of medicines in Poland. Diagnosis and proposed solutions” is a detailed analysis of restricted market availability of certain medicines and suggests a number of potential solutions, in particular in the area of reimbursement and pharmaceutical regulations.
The report “Costs of new drug technologies in the treatment of the most commonly diagnosed cancers. Forecast 2019-2021”
Monika Duszyńska is one of the authors of the report ‘Costs of new drug technologies in the treatment of the most commonly diagnosed cancers. Forecast 2019-2021’ prepared by the Institute of Health Management at Lazarski University. The report defines goals and tools required for an effective implementation of the health policy in the area of oncology.
Patients’ rights at Lazarski University
In April 2019 Monika Duszyńska conducted classes „Patients’ rights in connection with availability of healthcare services” at Lazarski University.
Debate „Biologicals and biosimilars – to make savings in order to be able to spend more”
On 30 July 2019 Monika Duszyńska took part in a panel in a debate „Biologicals and biosimilars – to make savings in order to be able to spend more”, organized by the Polish pharmaceutical industry chamber Izba Gospodarcza “Farmacja Polska”
Monika Duszyńska as an expert in the Polish Radio Channel 1
On 22 August Monika spoke, as an expert, in the Polish Radio, Channel 1, on biological medicines. We warmly invite you to listen to it (in Polish) at: https://www.polskieradio.pl/7/5098/Artykul/2357803,Sukces-inzynierii-genetycznej-lek-biologiczny
Interview for Rzeczpospolita
On 16 August 2018, Monika Duszyńska was interviewed by Paweł Rochowicz from Rzeczpospolita daily newspaper, where Monika spoke about biological and biosimilar medicines. We invite you to review the interview on-line at: https://www.rp.pl/RZECZoPRAWIE/180829956-Monika-Duszynska---Biorownowazny-nie-jest-wlasciwa-definicja-dla-lekow-biopodobnych.html
Public debate: “The medical reason of state – the theses for health”
On 29 June 2018, Monika Duszyńska attended a debate "Medical reason of state - the theses for health", under the Honorary Patronage of Fr. Cardinal Kazimierz Nycz. Her speech focused primarily on legislative challenges in healthcare.
The seminar dedicated to the interchangeability of biological medicines
The interchangeability of biological medicines still raises many controversies and doubts. On 18 June 2018 took place a seminar “Substitution-Interchangeability-Switch of biological drugs", fully dedicated to this topic. One of the speakers was Monika Duszyńska, who spoke on regulatory agencies’ and EU guidelines on switches and substitution of biological medicines.
Chambers Europe 2018
In 2018 edition of Chambers Europe international legal ranking, Lifesciences, Monika is ranked again in Band II as an individual lawyer. Chambers Europe reports: Head of practice Monika Duszyńska of Monika Duszyńska Kancelaria Adwokacka is referred to by sources as a "very renowned practitioner within the life sciences field." Clients appreciate that "she is very effective, positive and solution-oriented”.
Conference on Biological reference medicines and biosimilar medicines
On February 20, 2018, Monika Duszyńska spoke at the conference organized by Medical Pro Events. She raised a topic of the rules of the interchangeability of biological medicines which raises a number of doctors’ and patients’ concerns, including whether the patient's consent is required to change the medicine, what factors should be taken into account in the event of a possible change in therapy, how interchangeability is perceived by EU bodies and Member States of the European Union. Monika also talked about the guidelines of selected countries in the world concerning the principles of using biological medicines and about the [...]